Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Core Viewpoint - Enveric Biosciences, Inc. has entered into definitive agreements for the immediate exercise of certain outstanding warrants to purchase a total of 426,390 shares at specified exercise prices [1] Group 1: Company Actions - The company is advancing next-generation neuroplastogenic small molecules aimed at addressing psychiatric and neurological disorders [1] - The warrants were originally issued in February 2025 and September 2025, with exercise prices of $36.00 and $10.98 respectively [1]